EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will have CEO Nancy Lurker present at two virtual conferences: the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET and the 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The company focuses on developing therapeutics for serious eye disorders, including its Durasert® technology. Webcasts of the presentations will be available on their website, with replays accessible for 30 and 90 days, respectively.

WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at two upcoming virtual conferences:

• Jefferies London Healthcare Conference
  Forum: Corporate Presentation
  Date: Thursday, November 18, 2021
  Time: 3:00 a.m. ET

• 33rd Annual Piper Sandler Virtual Healthcare Conference
  Forum: Corporate Presentation
  Date: Monday, November 22^nd, 2021
  Time: 10:00 a.m. ET

A webcast and subsequent archived replay of each corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The Jefferies presentation replay will be available for 30 days after the event, and the Piper Sandler presentation will be available for 90 days after the event.

About EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert^® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ^®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU^®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What is the date and time of EyePoint Pharmaceuticals' presentation at the Jefferies London Healthcare Conference?

EyePoint Pharmaceuticals' presentation at the Jefferies London Healthcare Conference is scheduled for November 18, 2021, at 3:00 a.m. ET.

When will EyePoint Pharmaceuticals present at the Piper Sandler Virtual Healthcare Conference?

EyePoint Pharmaceuticals will present at the Piper Sandler Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET.

Where can I access the webcast of EyePoint Pharmaceuticals' presentations?

The webcast of EyePoint Pharmaceuticals' presentations can be accessed via the Investors section of their website.

How long will replays of EyePoint Pharmaceuticals' conference presentations be available?

The Jefferies presentation replay will be available for 30 days, and the Piper Sandler presentation will be available for 90 days after the event.

What innovative technology is EyePoint Pharmaceuticals developing?

EyePoint Pharmaceuticals is developing its proprietary Durasert® technology for sustained intraocular drug delivery.